Atomoxetine as an adjunct to nonpharmacological treatments for preventing vasovagal attacks in patients with recurrent vasovagal syncope: A pilot randomized-controlled trial.

Int J Cardiol Heart Vasc · 2021 · PMC8129927 · PMID 34027030

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

barely missed statistical significanceP = 0.053so close (0.05 < p ≤ 0.1)

Compared to placebo, the reduction in the primary efficacy endpoint at one month with atomoxetine barely missed statistical significance ( P = 0.053); however, atomoxetine significantly reduced the primary efficacy endpoint after three months ( P < 0.001).

also in 44 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.